Description:
The purpose of this study is to assess the safety, pharmacokinetics and tolerability,
describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD)
or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent
MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post
autologous stem cell transplant and are relapsed/refractory.
Title
- Brief Title: MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
- Official Title: A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Clinical Trial IDs
- ORG STUDY ID:
D7900C00001
- NCT ID:
NCT03489525
Conditions
- Relapsed/Refractory Multiple Myeloma
Interventions
Drug | Synonyms | Arms |
---|
Dose Escalation, MEDI2228, ADC (antibody drug conjugate) | | Dose Escalation, MEDI2228, ADC |
Dose Expansion, MEDI2228, ADC (antibody drug conjugate) | | Dose Expansion, MEDI2228, ADC |
Purpose
The purpose of this study is to assess the safety, pharmacokinetics and tolerability,
describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD)
or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent
MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post
autologous stem cell transplant and are relapsed/refractory.
Trial Arms
Name | Type | Description | Interventions |
---|
Dose Escalation, MEDI2228, ADC | Experimental | Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM). | - Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
|
Dose Expansion, MEDI2228, ADC | Experimental | Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with R/R MM in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase. | - Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
|
Eligibility Criteria
Inclusion Criteria:
1. Subjects must be ≥ 18 years of age at the time of screening.
2. Subjects must have a confirmed diagnosis of relapsed/refractory MM as per IMWG
criteria (Rajkumar et al, 2014) and have exhausted standard of care regimens with
proven clinical benefit, which include agents from the following anti myeloma
therapies: PIs, IMIDs, and mAbs and have measurable disease with at least one of the
following criteria:
1. Serum M-protein ≥ 0.5 g/dL
2. Urine M-protein ≥ 200 mg/24 hours
3. Serum free light chain (FLC) assay: involved FLC level ≥ 10 mg/dL provided serum
FLC ratio is abnormal.
3. Subjects must either be ineligible for or post-autologous stem cell transplant.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
5. Adequate organ and marrow functions as determined per protocol-defined criteria.
Exclusion Criteria
Any of the following would exclude the subject from participation in the study:
Target Disease:
1. Subjects who have previously received an autologous stem cell transplant if less than
90 days have elapsed from the time of transplant or the subject has not recovered from
transplant associated toxicities prior to the first scheduled dose of MEDI2228
2. Subjects who have previously received an allogeneic stem cell transplant
3. Central nervous system (CNS) involvement(including meningeal involvement) by MRI or
cerebrospinal fluid exam
4. Known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,
skin changes (POEMS) syndrome, plasma cell leukemia, Waldenstrom's macroglobulinemia,
or amyloidosis
Medical History and Concurrent Diseases:
5. Any condition that, in the opinion of the investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or study
results
Maximum Eligible Age: | 101 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Occurrence of adverse events (AEs) |
Time Frame: | From time of informed consent through 90 days post end of treatment |
Safety Issue: | |
Description: | To assess by the occurrence of adverse events (AEs) |
Secondary Outcome Measures
Measure: | MEDI2228 maximum observed concentration for PK |
Time Frame: | From time of informed consent through 60 days post end of treatment |
Safety Issue: | |
Description: | To assess the pharmacokinetics of MEDI2228 |
Measure: | MEDI2228 area under the concentration-time curve for PK |
Time Frame: | From time of informed consent through 60 days post end of treatment |
Safety Issue: | |
Description: | To assess the pharmacokinetics of MEDI2228 |
Measure: | MEDI2228 clearance for PK |
Time Frame: | From time of informed consent through 60 days post end of treatment |
Safety Issue: | |
Description: | To assess the pharmacokinetics of Medi2228 |
Measure: | MEDI2228 terminal half-life for PK |
Time Frame: | From time of informed consent through 60 days post end of treatment |
Safety Issue: | |
Description: | To assess the pharmacokinetics of MEDI2228 |
Measure: | Number of subjects who develop anti-drug antibodies (ADAs) |
Time Frame: | From time of informed consents through 60 days post end of treatment |
Safety Issue: | |
Description: | To assess immunogenicity of MEDI2228 |
Measure: | Objective response rate (ORR) |
Time Frame: | From time of informed consent and up to three years after final patient is enrolled |
Safety Issue: | |
Description: | To assess the anti-tumor activity of MEDI2228 |
Measure: | Clinical benefit rate |
Time Frame: | From time of informed consent up to three years after final patient is enrolled |
Safety Issue: | |
Description: | To assess clinical benefit of MEDI2228 |
Measure: | Duration of response (DoR) |
Time Frame: | From time of informed consent and up to three years after final patient is enrolled |
Safety Issue: | |
Description: | To assess the anti-tumor activity of MEDI2228 |
Measure: | Progression free survival (PFS) |
Time Frame: | From time of informed consent and up to three years after final patient is enrolled |
Safety Issue: | |
Description: | To assess the anti-tumor activity of MEDI2228 |
Measure: | Overall Survival (OS) |
Time Frame: | From time of informed consent and up to three years after final patient is enrolled |
Safety Issue: | |
Description: | To assess the anti-tumor activity of MEDI2228 |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | MedImmune LLC |
Trial Keywords
- multiple myeloma
- relapsed/refractory
- open-label
Last Updated
August 5, 2021